Adastra Holdings Announces Resignation of Director
Adastra Holdings (CSE: XTRX) (FSE: D2EP), a leading cannabis processor and producer of concentrates brands, announced that Andrew Hale has resigned from his position as director, effective February 14, 2025. The company's board of directors is actively searching for a replacement to fill the upcoming vacancy and will provide updates when available. Adastra, which focuses on product innovation and commercialization for adult-use and medical markets, is known for producing two of Canada's top concentrate brands.
Adastra Holdings (CSE: XTRX) (FSE: D2EP), un importante processore di cannabis e produttore di marchi di concentrati, ha annunciato che Andrew Hale si è dimesso dalla sua posizione di direttore, con effetto 14 febbraio 2025. Il consiglio di amministrazione dell'azienda sta attivamente cercando un sostituto per coprire il prossimo posto vacante e fornirà aggiornamenti non appena disponibili. Adastra, che si concentra sull'innovazione del prodotto e sulla commercializzazione per i mercati per uso adulto e medico, è nota per la produzione di due dei marchi di concentrato più apprezzati del Canada.
Adastra Holdings (CSE: XTRX) (FSE: D2EP), un importante procesador de cannabis y productor de marcas de concentrados, anunció que Andrew Hale ha dimitido de su cargo como director, con efecto a partir del 14 de febrero de 2025. La junta directiva de la compañía está buscando activamente un reemplazo para llenar la próxima vacante y proporcionará actualizaciones cuando estén disponibles. Adastra, que se centra en la innovación de productos y la comercialización para mercados de uso adulto y médico, es conocida por producir dos de las principales marcas de concentrados de Canadá.
아다스트라 홀딩스 (CSE: XTRX) (FSE: D2EP)는 주요 대마초 가공업체이자 농축 브랜드 생산자로서 앤드류 헤일이 이사직에서 사임했다고 발표했습니다. 사임 효력일은 2025년 2월 14일입니다. 회사 이사회는 다가오는 공석을 채우기 위한 대체 인물을 적극적으로 찾고 있으며 업데이트가 있을 시 시기적절히 제공할 예정입니다. 아다스트라는 성인 사용 및 의료 시장을 위한 제품 혁신과 상업화에 집중하며, 캐나다에서 가장 유명한 두 개의 농축 브랜드를 생산하는 것으로 알려져 있습니다.
Adastra Holdings (CSE: XTRX) (FSE: D2EP), un important transformateur de cannabis et producteur de marques de concentrés, a annoncé que Andrew Hale a démissionné de son poste de directeur, avec effet à partir du 14 février 2025. Le conseil d'administration de l'entreprise recherche activement un remplaçant afin de combler le prochain poste vacant et fournira des mises à jour dès qu'elles seront disponibles. Adastra, qui se concentre sur l'innovation des produits et la commercialisation pour les marchés de l'usage adulte et médical, est connue pour produire deux des principales marques de concentrés au Canada.
Adastra Holdings (CSE: XTRX) (FSE: D2EP), ein führender Hersteller und Verarbeiter von Cannabis und Konzentraten, gab bekannt, dass Andrew Hale mit Wirkung zum 14. Februar 2025 von seinem Posten als Direktor zurückgetreten ist. Der Vorstand des Unternehmens ist aktiv auf der Suche nach einem Nachfolger, um die bevorstehende Vakanz zu füllen, und wird Updates bereitstellen, sobald diese verfügbar sind. Adastra, das sich auf Produktinnovation und -kommerzialisierung für den Freizeit- und medizinischen Markt konzentriert, ist bekannt für die Herstellung von zwei der führenden Konzentraten-Marken Kanadas.
- None.
- None.
Langley, British Columbia--(Newsfile Corp. - February 3, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian concentrates brands with a focus on product innovation and commercialization for adult-use and medical markets, announces today that Andrew Hale has tendered his resignation as a director of the Company effective as of February 14, 2025. The Company thanks Mr. Hale for his service as a member of the board of directors. The remaining directors are in the process of identifying a candidate to fill the pending vacancy and will provide an update once available.
About Adastra Holdings Ltd.
Adastra has become one of Canada's leaders in the supply and manufacturing of ethnobotanical and cannabis products for lawful adult-use. It serves medical markets and engages in forward-looking therapeutic applications. With cannabis concentrate products sold through retailers at more than 2,000 locations across Canada, Adastra's Phyto Extractions and Endgame Extracts brands are now well established with a growing distribution presence. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. Adastra partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market, with the ultimate aim of addressing the needs of patients. For more information, visit: www.adastraholdings.ca.
For additional information, please contact:
(778) 715 5011
info@adastraholdings.ca
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking information" as defined under applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding the identification of a candidate to fill the pending vacancy on the board of directors and the Company's intention to provide an update once available. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in consumer demand and preferences; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in the Company's management's discussion and analysis for the nine months ended September 30, 2024, filed with Canadian securities regulators and available on the Company's profile on SEDAR+ at www.sedarplus.ca.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239467
FAQ
When will Andrew Hale's resignation from Adastra Holdings (XTRX) take effect?
What is Adastra Holdings' (XTRX) main business focus?
How is Adastra Holdings (XTRX) handling the director vacancy?
What stock exchanges is Adastra Holdings (XTRX) listed on?
